Tumour-Induced Osteomalacia Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Report
255 Pages
January 2024
Region: Global
Fairfield Market Research
ID: 5924979

In 2024, the global tumour-induced osteomalacia market recorded impressive revenue of US$ 135 Mn and the market is poised for further advancement, projecting to attain US$ 173 Mn by the year 2031.

What's Paving the Way for Tumour-Induced Osteomalacia Product Manufacturers?

'Vast Clinical Pipeline for Orphan Drug Development'

The field of medical research continually seeks to address unmet medical needs, and breakthroughs in cellular biology have illuminated pathways towards novel therapeutics. Small molecules like inhibitors are becoming pivotal in comprehending cellular microenvironments and signaling pathways. These molecules offer improved patient tolerability alongside treatment efficacy.

Notably, the tumour-induced osteomalacia treatment landscape boasts a limited clinical pipeline, with only one approved drug, Crystiva, manufactured by Ultragenix Pharmaceuticals and Kyowa Hakko Kirin Co., Ltd., along with its small molecule inhibitor Fibroblast growth factor 23 (FGF-23). This scarcity presents an opportune arena for pharmaceutical companies to invest in pioneering drug discoveries for underserved targets.

What Challenges Are Affecting Tumour-Induced Osteomalacia Demand?

'High-Cost of Treatment and Stringent Regulations'

The cost of treating tumour-induced osteomalacia can be substantial, hindering market expansion. Surgical procedures for tumour removal can cost between US$ 50,000 to US$ 100,000 in the U.S., with the annual expense for all treatments reaching billions.

Additionally, pricing sensitivity in emerging markets presents barriers to addressing rare diseases. Strict regulations governing cancer and immunological drugs on a global scale, including adherence to FDA and other standards, pose further challenges.

Regional Insights:

Why the U.S. Dominates the Tumour-Induced Osteomalacia Market?

Developed Healthcare Infrastructure & Fund Allocation for Rare Disease Therapeutics

The U.S. accounted for a significant market share in the global tumour-induced osteomalacia market in 2024. Its prominence can be attributed to a highly developed research infrastructure, strong collaborations between research institutes and hospitals, and dedicated programs and funds allocated for orphan drug development and rare disease research.

Japan: A Growing Market for Tumour-Induced Osteomalacia?

Growing Regulatory Approvals for Marketing in the Country

Japan is poised to exhibit growth in the global tumour-induced osteomalacia market with the emergence of new treatment modalities, post-marketing approvals, and the adoption of drugs approved by the FDA and EU. For instance, in August 2022, the European Commission granted Kyowa Kirin authorization to use CRYSVITA® (burosumab) as a therapy for tumor-induced osteomalacia.

India's Potential in the Tumour-Induced Osteomalacia Market

Large Patient Population and Huge Potential for New Market Entrants

India, with a notable market share in 2024, is projected to expand in the global tumour-induced osteomalacia market. Its burgeoning patient base and growing economy offer substantial opportunities for drug manufacturers, despite pricing competition. India presents lucrative prospects for manufacturing collaborations in the tumour-induced osteomalacia market space.

Competitive Landscape:

Leading pharmaceutical companies focus on partnerships to expand product portfolios. Emerging markets see continuous R&D investments, facilitating the development of new pharmaceuticals and drug combinations.

Key Companies Profiled:

Ultragenyx Pharmaceutical Inc.
Dishman Carbogen Amcis Ltd.
Teva Pharmaceuticals
Glenmark Pharmaceuticals
Wockhardt Ltd
FDC Limited
Lupin Pharmaceuticals
Zydus Cadila Healthcare Ltd.
Intas Pharmaceuticals Ltd
Macleods Pharmaceuticals
G.C. Chemie Pharmie Ltd
Santiago Life Sciences

Tumour-Induced Osteomalacia Industry Research Segmentation

Tumour-Induced Osteomalacia Market by Treatment:

Drugs and Supplements
Burosumab -twza
Cinarcalcet
Calcium
Active Vitamin D (Calcitriol/α-calcitriol)
Phosphorus
Surgery

Tumour-Induced Osteomalacia Market by Diagnosis:

Laboratories
Elevated Blood Fibroblast Growth Factor 23 (FGF-23)
Serum Calcium, PTH, Vitamin D
Hyperphosphaturia (Secondary Effects of FDF-23)
Hypophosphatemia (Secondary Effects of FDF-23)
Bone Scan
Magnetic Resonance Imaging (MRI)
Computed Tomography (CT Scans)
Differential Diagnosis
Vitamin D Metabolism and Deficiency
Osteoporosis
Renal Osteodystrophy
Others

Tumour-Induced Osteomalacia Market by End User:

Hospitals
Specialty Clinics
Others

Tumour-Induced Osteomalacia Market by Country:

U.S.
Canada
Japan
European Countries
China
Mexico
South Korea
India
Brazil
Australia

This product will be delivered within 1-3 business days.

1. Executive Summary

1.1. Global Tumour-Induced Osteomalacia Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Tumour-Induced Osteomalacia Market Outlook, 2018 - 2031

3.1. Global Tumour-Induced Osteomalacia Market Outlook, by Treatment, Value (US$ Mn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Drugs and Supplements
3.1.1.1.1. Burosumab -twza
3.1.1.1.2. Cinarcalcet
3.1.1.1.3. Calcium
3.1.1.1.4. Active Vitamin D (Calcitriol/a-calcitriol)
3.1.1.1.5. Phosphorus
3.1.1.2. Surgery
3.2. Global Tumour-Induced Osteomalacia Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Hospitals
3.2.1.2. Specialty Clinics
3.2.1.3. Others
3.3. Global Tumour-Induced Osteomalacia Market Outlook, by Diagnosis, Value (US$ Mn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Laboratories
3.3.1.1.1. Elevated Blood Fibroblast Growth Factor 23 (FGF-23)
3.3.1.1.2. Serum Calcium, PTH, Vitamin D
3.3.1.1.3. Hyperphosphaturia (Secondary Effects of FDF-23)
3.3.1.1.4. Hypophosphatemia (Secondary Effects of FDF-23)
3.3.1.2. Bone Scan
3.3.1.2.1. Magnetic Resonance Imaging (MRI)
3.3.1.2.2. Computed Tomography (CT scans)
3.3.1.3. Differential Diagnosis
3.3.1.3.1. Vitamin D Metabolism and Deficiency
3.3.1.3.2. Osteoporosis
3.3.1.3.3. Renal Osteodystrophy
3.3.1.3.4. Others
3.4. Global Tumour-Induced Osteomalacia Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa

4. North America Tumour-Induced Osteomalacia Market Outlook, 2018 - 2031

4.1. North America Tumour-Induced Osteomalacia Market Outlook, by Treatment, Value (US$ Mn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Drugs and Supplements
4.1.1.1.1. Burosumab -twza
4.1.1.1.2. Cinarcalcet
4.1.1.1.3. Calcium
4.1.1.1.4. Active Vitamin D (Calcitriol/a-calcitriol)
4.1.1.1.5. Phosphorus
4.1.1.2. Surgery
4.2. North America Tumour-Induced Osteomalacia Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Hospitals
4.2.1.2. Specialty Clinics
4.2.1.3. Others
4.3. North America Tumour-Induced Osteomalacia Market Outlook, by Diagnosis, Value (US$ Mn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Laboratories
4.3.1.1.1. Elevated Blood Fibroblast Growth Factor 23 (FGF-23)
4.3.1.1.2. Serum Calcium, PTH, Vitamin D
4.3.1.1.3. Hyperphosphaturia (Secondary Effects of FDF-23)
4.3.1.1.4. Hypophosphatemia (Secondary Effects of FDF-23)
4.3.1.2. Bone Scan
4.3.1.2.1. Magnetic Resonance Imaging (MRI)
4.3.1.2.2. Computed Tomography (CT scans)
4.3.1.3. Differential Diagnosis
4.3.1.3.1. Vitamin D Metabolism and Deficiency
4.3.1.3.2. Osteoporosis
4.3.1.3.3. Renal Osteodystrophy
4.3.1.4. Others
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Tumour-Induced Osteomalacia Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
4.4.1.2. U.S. Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
4.4.1.3. U.S. Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
4.4.1.4. Canada Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
4.4.1.5. Canada Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
4.4.1.6. Canada Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Tumour-Induced Osteomalacia Market Outlook, 2018 - 2031

5.1. Europe Tumour-Induced Osteomalacia Market Outlook, by Treatment, Value (US$ Mn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Drugs and Supplements
5.1.1.1.1. Burosumab -twza
5.1.1.1.2. Cinarcalcet
5.1.1.1.3. Calcium
5.1.1.1.4. Active Vitamin D (Calcitriol/a-calcitriol)
5.1.1.1.5. Phosphorus
5.1.1.2. Surgery
5.2. Europe Tumour-Induced Osteomalacia Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Hospitals
5.2.1.2. Specialty Clinics
5.2.1.3. Others
5.3. Europe Tumour-Induced Osteomalacia Market Outlook, by Diagnosis, Value (US$ Mn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Laboratories
5.3.1.1.1. Elevated Blood Fibroblast Growth Factor 23 (FGF-23)
5.3.1.1.2. Serum Calcium, PTH, Vitamin D
5.3.1.1.3. Hyperphosphaturia (Secondary Effects of FDF-23)
5.3.1.1.4. Hypophosphatemia (Secondary Effects of FDF-23)
5.3.1.2. Bone Scan
5.3.1.2.1. Magnetic Resonance Imaging (MRI)
5.3.1.2.2. Computed Tomography (CT scans)
5.3.1.3. Differential Diagnosis
5.3.1.3.1. Vitamin D Metabolism and Deficiency
5.3.1.3.2. Osteoporosis
5.3.1.3.3. Renal Osteodystrophy
5.3.1.4. Others
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Tumour-Induced Osteomalacia Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
5.4.1.2. Germany Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.3. Germany Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
5.4.1.4. U.K. Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
5.4.1.5. U.K. Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.6. U.K. Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
5.4.1.7. France Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
5.4.1.8. France Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.9. France Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
5.4.1.10. Italy Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
5.4.1.11. Italy Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.12. Italy Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
5.4.1.13. Turkey Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
5.4.1.14. Turkey Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.15. Turkey Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
5.4.1.16. Russia Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
5.4.1.17. Russia Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.18. Russia Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
5.4.1.19. Rest of Europe Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
5.4.1.20. Rest of Europe Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.21. Rest of Europe Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Tumour-Induced Osteomalacia Market Outlook, 2018 - 2031

6.1. Asia Pacific Tumour-Induced Osteomalacia Market Outlook, by Treatment, Value (US$ Mn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Drugs and Supplements
6.1.1.1.1. Burosumab -twza
6.1.1.1.2. Cinarcalcet
6.1.1.1.3. Calcium
6.1.1.1.4. Active Vitamin D (Calcitriol/a-calcitriol)
6.1.1.1.5. Phosphorus
6.1.1.2. Surgery
6.2. Asia Pacific Tumour-Induced Osteomalacia Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Hospitals
6.2.1.2. Specialty Clinics
6.2.1.3. Others
6.3. Asia Pacific Tumour-Induced Osteomalacia Market Outlook, by Diagnosis, Value (US$ Mn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Laboratories
6.3.1.1.1. Elevated Blood Fibroblast Growth Factor 23 (FGF-23)
6.3.1.1.2. Serum Calcium, PTH, Vitamin D
6.3.1.1.3. Hyperphosphaturia (Secondary Effects of FDF-23)
6.3.1.1.4. Hypophosphatemia (Secondary Effects of FDF-23)
6.3.1.2. Bone Scan
6.3.1.2.1. Magnetic Resonance Imaging (MRI)
6.3.1.2.2. Computed Tomography (CT scans)
6.3.1.3. Differential Diagnosis
6.3.1.3.1. Vitamin D Metabolism and Deficiency
6.3.1.3.2. Osteoporosis
6.3.1.3.3. Renal Osteodystrophy
6.3.1.4. Others
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Tumour-Induced Osteomalacia Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
6.4.1.2. China Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.3. China Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
6.4.1.4. Japan Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
6.4.1.5. Japan Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.6. Japan Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
6.4.1.7. South Korea Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
6.4.1.8. South Korea Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.9. South Korea Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
6.4.1.10. India Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
6.4.1.11. India Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.12. India Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
6.4.1.13. Southeast Asia Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
6.4.1.14. Southeast Asia Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.15. Southeast Asia Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Tumour-Induced Osteomalacia Market Outlook, 2018 - 2031

7.1. Latin America Tumour-Induced Osteomalacia Market Outlook, by Treatment, Value (US$ Mn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Drugs and Supplements
7.1.1.1.1. Burosumab -twza
7.1.1.1.2. Cinarcalcet
7.1.1.1.3. Calcium
7.1.1.1.4. Active Vitamin D (Calcitriol/a-calcitriol)
7.1.1.1.5. Phosphorus
7.1.1.2. Surgery
7.2. Latin America Tumour-Induced Osteomalacia Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
7.2.1.1. Hospitals
7.2.1.2. Specialty Clinics
7.2.1.3. Others
7.3. Latin America Tumour-Induced Osteomalacia Market Outlook, by Diagnosis, Value (US$ Mn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Laboratories
7.3.1.1.1. Elevated Blood Fibroblast Growth Factor 23 (FGF-23)
7.3.1.1.2. Serum Calcium, PTH, Vitamin D
7.3.1.1.3. Hyperphosphaturia (Secondary Effects of FDF-23)
7.3.1.1.4. Hypophosphatemia (Secondary Effects of FDF-23)
7.3.1.2. Bone Scan
7.3.1.2.1. Magnetic Resonance Imaging (MRI)
7.3.1.2.2. Computed Tomography (CT scans)
7.3.1.3. Differential Diagnosis
7.3.1.3.1. Vitamin D Metabolism and Deficiency
7.3.1.3.2. Osteoporosis
7.3.1.3.3. Renal Osteodystrophy
7.3.1.4. Others
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Tumour-Induced Osteomalacia Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
7.4.1.2. Brazil Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
7.4.1.3. Brazil Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
7.4.1.4. Mexico Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
7.4.1.5. Mexico Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
7.4.1.6. Mexico Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
7.4.1.7. Argentina Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
7.4.1.8. Argentina Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
7.4.1.9. Argentina Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
7.4.1.10. Rest of Latin America Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
7.4.1.11. Rest of Latin America Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
7.4.1.12. Rest of Latin America Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Tumour-Induced Osteomalacia Market Outlook, 2018 - 2031

8.1. Middle East & Africa Tumour-Induced Osteomalacia Market Outlook, by Treatment, Value (US$ Mn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Drugs and Supplements
8.1.1.1.1. Burosumab -twza
8.1.1.1.2. Cinarcalcet
8.1.1.1.3. Calcium
8.1.1.1.4. Active Vitamin D (Calcitriol/a-calcitriol)
8.1.1.1.5. Phosphorus
8.1.1.2. Surgery
8.2. Middle East & Africa Tumour-Induced Osteomalacia Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Hospitals
8.2.1.2. Specialty Clinics
8.2.1.3. Others
8.3. Middle East & Africa Tumour-Induced Osteomalacia Market Outlook, by Diagnosis, Value (US$ Mn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Laboratories
8.3.1.1.1. Elevated Blood Fibroblast Growth Factor 23 (FGF-23)
8.3.1.1.2. Serum Calcium, PTH, Vitamin D
8.3.1.1.3. Hyperphosphaturia (Secondary Effects of FDF-23)
8.3.1.1.4. Hypophosphatemia (Secondary Effects of FDF-23)
8.3.1.2. Bone Scan
8.3.1.2.1. Magnetic Resonance Imaging (MRI)
8.3.1.2.2. Computed Tomography (CT scans)
8.3.1.3. Differential Diagnosis
8.3.1.3.1. Vitamin D Metabolism and Deficiency
8.3.1.3.2. Osteoporosis
8.3.1.3.3. Renal Osteodystrophy
8.3.1.4. Others
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Tumour-Induced Osteomalacia Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
8.4.1.2. GCC Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.3. GCC Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
8.4.1.4. South Africa Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
8.4.1.5. South Africa Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.6. South Africa Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
8.4.1.7. Egypt Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
8.4.1.8. Egypt Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.9. Egypt Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
8.4.1.10. Nigeria Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
8.4.1.11. Nigeria Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.12. Nigeria Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Tumour-Induced Osteomalacia Market by Treatment, Value (US$ Mn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Tumour-Induced Osteomalacia Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Tumour-Induced Osteomalacia Market by Diagnosis, Value (US$ Mn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Distribution Channel vs by End User Heat map
9.2. Manufacturer vs by End User Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Ultragenyx Pharmaceutical Inc.
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Dishman Carbogen Amcis Ltd.
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Teva Pharmaceuticals
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Glenmark Pharmaceuticals
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Wockhardt Ltd
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. FDC Limited
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Lupin Pharmaceuticals
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Intas Pharmaceuticals Ltd
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Zydus Cadila Healthcare Ltd.
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Macleods Pharmaceuticals
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

Ultragenyx Pharmaceutical Inc.
Dishman Carbogen Amcis Ltd.
Teva Pharmaceuticals
Glenmark Pharmaceuticals
Wockhardt Ltd
FDC Limited
Lupin Pharmaceuticals
Zydus Cadila Healthcare Ltd.
Intas Pharmaceuticals Ltd
Macleods Pharmaceuticals
G.C. Chemie Pharmie Ltd
Santiago Life Sciences

Methodology

LOADING...